In the same filing, it was noted that Callicutt acquired 40,000 shares of common stock at no additional cost through the vesting of restricted stock units. This acquisition did not involve any monetary exchange. Following these transactions, Callicutt holds 7,614 shares directly. InvestingPro subscribers can access additional insights, including 8 more key tips about GALT's financial health and market position. InvestingPro subscribers can access additional insights, including 8 more key tips about GALT's financial health and market position.
In the same filing, it was noted that Callicutt acquired 40,000 shares of common stock at no additional cost through the vesting of restricted stock units. This acquisition did not involve any monetary exchange. Following these transactions, Callicutt holds 7,614 shares directly.
In other recent news, Galectin Therapeutics (NASDAQ:GALT) revealed encouraging results from its NAVIGATE clinical trial, indicating that belapectin may reduce the development of esophageal varices in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension. The trial, which spanned over 130 sites worldwide, involved 355 patients who received belapectin or a placebo for 18 months. In those who completed the trial with required endoscopies, belapectin at 2mg/kg of lean body mass showed a 48.9% reduction in the incidence of varices compared to placebo. However, the drug did not meet the primary endpoint of statistical significance in the broader intent-to-treat population.
Non-invasive measures supported these findings, with liver stiffness assessments showing a 50% lower number of subjects with worsening stiffness among those treated with belapectin. Galectin Therapeutics remains optimistic about belapectin's potential and is actively seeking pharmaceutical partnerships to advance its development. Despite financial challenges, as indicated by a current ratio of 1.13 and negative earnings per share of -$0.73, analysts maintain an $11 price target, suggesting significant upside potential. These are among the recent developments for Galectin Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.